Ionis Pharmaceuticals Inc at Guggenheim Securities Inflammation & Immunology Conference Transcript
Good morning and thank you for joining us at Guggenheim's 5th Annual I&I and Neurology Conference, I am Debjit and it's our privilege to host Onaiza Cadoret, EVP and Chief Global Product Strategy and Operational Officer at Ionis along with Brett Monia, Chief Executive Officer. Thank you. Thank you both for your time today. Brett, why don't you sort of lead us off with an overview of the company heading into a very data-rich period for Ionis over the next 2 years?
Sure. Happy to, Debjit and good morning, everybody. Thank you for the opportunity to be here and speak on behalf of Ionis. So we -- Ionis is right now on the cusp of really driving substantial value for all Ionis stakeholders today. Looking back to last year, we had a very positive Phase III data for eplontersen in TTR amyloidosis with polyneuropathy. This year, we had a drug approval, QALSODY, for SOD1-ALS, which
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |